Results from BIG D-FOOT study using STIMULAN® when treating DFO to be presented at EBJIS 2025
- Randomised, double-blinded, controlled BIG D-FOOT study demonstrates that local antibiotic delivery using STIMULAN® significantly reduces post-surgical infective complications in patients with diabetic foot osteomyelitis (DFO)
- Biocomposites symposium will explore best practice treatment strategies for complex infections and share findings from the BIG D FOOT study
Keele, UK, 9 September 2025 – Biocomposites, an international medical devices company that engineers, manufactures and markets world-leading products for use in infection management in bone and soft tissue, today announces its participation as a Platinum Sponsor of the 43rd Annual Meeting of the European Bone & Joint Infection Society (EBJIS), taking place on 11-13 September 2025 at the Bologna Congress Centre in Bologna, Italy.
